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Cerebrovascular pathology in Down
syndrome and Alzheimer disease
Elizabeth Head1*, Michael J. Phelan2, Eric Doran3, Ronald C. Kim4, Wayne W. Poon5, Frederick A. Schmitt1,7
and Ira T. Lott3,6

Abstract
People with Down syndrome (DS) are at high risk for developing Alzheimer disease (AD) with age. Typically, by age
40 years, most people with DS have sufficient neuropathology for an AD diagnosis. Interestingly, atherosclerosis and
hypertension are atypical in DS with age, suggesting the lack of these vascular risk factors may be associated with
reduced cerebrovascular pathology. However, because the extra copy of APP leads to increased beta-amyloid peptide
(Aβ) accumulation in DS, we hypothesized that there would be more extensive and widespread cerebral amyloid
angiopathy (CAA) with age in DS relative to sporadic AD. To test this hypothesis CAA, atherosclerosis and arteriolosclerosis
were used as measures of cerebrovascular pathology and compared in post mortem tissue from individuals with DS
(n = 32), sporadic AD (n = 80) and controls (n = 37). CAA was observed with significantly higher frequencies in brains of
individuals with DS compared to sporadic AD and controls. Atherosclerosis and arteriolosclerosis were rare in the cases
with DS. CAA in DS may be a target for future interventional clinical trials.
Keywords: Arteriolosclerosis, Atherosclerosis, Cerebral amyloid angiopathy, Trisomy 21, Vascular risk factors

Introduction
People with Down syndrome (DS) are at higher risk for
developing Alzheimer disease (AD), which is thought to
be primarily due to the overexpression of amyloid precursor protein [19, 46]. Beta-amyloid (Aβ) plaques and
neurofibrillary tangles are typically observed by 40 years
of age (reviewed in [27], with dementia onset most typically occurring almost a decade later [26, 35, 36, 52]. Up
to 55% of people with DS between 40 and 49 years of
age develop dementia and the numbers rise to 77% in
people 60–69 years of age (reviewed in [6]).
There is increasing recognition of the vascular contribution to cognitive impairment and dementia (VCID; [33,
37]). The presence of cerebrovascular pathology may be a
critical comorbidity that accelerates the age of onset of dementia and also leads to faster disease progression. In the
general population, ~6%–45% of autopsy cases show
mixed AD neuropathology with cerebrovascular pathology
[32]. Cerebrovascular pathology resulting from atherosclerosis and arteriolosclerosis may serve as a “second hit”
* Correspondence: elizabeth.head@uky.edu
1
University of Kentucky, Sanders-Brown Center on Aging, 800 South
Limestone Street, Lexington, KY 40536, USA
Full list of author information is available at the end of the article

necessary for conversion to dementia particularly when
significant Aβ is present in the brain [33, 47]. Atherosclerosis is thought to be a major contributor to VCID as is
arteriolosclerosis [1, 29, 33]. Cerebral amyloid angiopathy
(CAA) is also observed frequently in AD [3, 15, 25, 38]
and may lead to microhemorrhages and infarcts [57].
VCID in DS has been less well studied [60] but is
thought to be rare based upon fewer vascular risk factors
being present in DS (e.g. hypertension, atherosclerosis,
smoking) [45]. In a recent neuroimaging study using
T2*and susceptibility weighted imaging, the location and
number of microbleeds were evaluated in 91 nondemented and 26 individuals with DS [14]. CAA in people with
DS was present in 31% of symptomatic DS participants,
which was similar to that observed in sporadic AD (38%).
Microbleeds observed by neuroimaging may be larger
than the smaller bleeds that can be observed at autopsy
and may underrepresent the extent of this vascular pathology in DS. At autopsy, CAA has been reported in small
autopsy studies of people with DS over the age of 55 years
[30, 35] or in case reports [8, 18, 40] with CAA also containing post-translationally modified Aβ [23]. However,
the accumulation of CAA as a function of age in DS has
yet to be explored. Extensive cerebrovascular hemorrhages
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and stroke are associated with CAA in DS [8, 18, 31, 39,
40, 43] in most studies but not in all [30, 35]; the majority
of these studies are based on small autopsy series or case
reports. Despite increased CAA in DS with age, VCID (or
multi-infarct dementia as it was termed then [16]) is rare
with only one case report in the literature of a 55-year old
woman with DS.
It is important to note that people with DS show virtually no evidence for several of the risk factors for cerebrovascular pathology particularly atherosclerosis and
hypertension [12, 20, 21, 41, 42, 61]. Thus, the purpose of
our study was two-fold. First, we sought to characterize
the frequency of cerebrovascular pathology (defined as
atherosclerosis, arteriolosclerosis and CAA) in a series of
autopsy cases with DS and AD with direct comparison to
sporadic AD and nondemented controls. Second, we
hypothesized that cerebrovascular pathology associated
with atherosclerosis would be less frequent in DS relative
to non-DS AD cases. It is interesting to note that these
vascular pathologies have not been directly compared in
DS and AD cases.

Methods and methods
This study examined prevalence of cerebrovascular pathology in three University of California at Irvine Alzheimer Disease Research Center (UCI ADRC) cohorts
including DS cases, sporadic AD cases and nondemented control cases. All AD cases, sporadic AD and DS
with AD (Braak neurofibrillary tangle (NFT) stage VI
and amyloid plaque stage C), were selected based upon
neuropathological criteria collected using the recently
revised National Alzheimer Disease Coordinating Center
(NACC) guidelines [28]. DS cases were all demented at
the time of death based upon DSM-IV criteria [56] Atherosclerosis was evaluated using procedures described by
Beach and colleagues (2007) [7] with the Circle of Willis
being graded by gross visual inspection and rated as
none, mild (0–25% obstruction), moderate (26–60%
obstruction) or severe (> 60% obstruction). Arteriolosclerosis was determined by H&E staining of the thalamus and subthalamic nuclei, basal ganglia, middle
frontal gyrus, superior & middle temporal gyrus, inferior
parietal lobule, and occipital cortex [28]. Arteriolosclerosis, as described by Grinberg and colleagues (2010)
included concentric hyaline thickening of small arteries
(40–150 μm in diameter) associated with a concentric
stenosis of the vessel lumen [25]. Arteriolosclerosis was
noted as being mild, moderate or severe based upon the
severity of hyalinosis of the media and adventitia of
small parenchymal and/or leptomeningeal vessels. CAA
was scored based upon Aβ immunostaining as none,
mild, moderate or severe. Nondemented control cases
were selected to be Braak NFT stage 0, I or II and amyloid plaque stage 0 or A [11]. Data collected using the
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NACC vascular pathology forms at the UCI ADRC describing atherosclerosis, arteriolosclerosis and amyloid
angiopathy (or CAA) were used [28]. A total of 149
cases were evaluated, including 32 from the DS cohort,
80 from the AD cohort, and 37 control cases. Demographic characteristics are shown by cohort in Table 1.
Similar numbers of males and females were observed in
the DS and AD cohorts, but more males were represented in the control cohort. The average age at death
was lowest in the DS cohort, and highest in the control
cohort (Table 1).

Relative risk analysis

To determine the relative risk of each of the cerebrovascular outcome measures for the three cohorts, pathological
outcomes were dichotomized to indicate the presence/absence of each cerebrovascular event. The risk of a positive
finding was then calculated for each cohort, separately.
Ninety-five percent confidence intervals were based on
the score test for binomial outcomes [2]. Two AD cases
were missing measures of atherosclerosis but other measures were available, thus they were excluded from the
analysis when comparing atherosclerosis across groups.

Regression analysis

To test the hypothesis that the DS cohort was less likely
to have atherosclerosis or arteriolosclerosis but more
likely to have CAA than sporadic AD and control cases,
we used multinomial logistic regression. Atherosclerosis,
arteriolosclerosis and CAA were graded on an ordinal
scale: none, mild, moderate to severe. Cumulative logistic regression was used to model the probability of the
severity of CAA findings based on the autopsy case cohort [2]. The cumulative-logit models thus represent the
full range of severity and allow for tests of whether each
of the cohorts was associated with progressive degrees
of severity for each of the cerebrovascular outcomes.
All computations were executed in the graphical and
programming environment R [48].
Table 1 Characteristics of participants by cohort
Cohort
a

Characteristic

AD (n = 80)

DS (n = 32)

Ctrl (n = 37)

Age-at-autopsy (yrs)

76.08 (12.21)

55.23 (6.64)

80.27 (10.04)

Male

39 (49%)

16 (50%)

22 (59%)

Female

40 (50%)

15 (47%)

15 (41%)

Missing

1 (1.2%)

1 (3.1%)

0 (0%)

Sex

a

Means (standard deviation) calculated on a complete-case basis. Female
shows the number (percent) of females in the sample. There were two cases
with missing entries for their sex
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Results
Observations had been recorded using the NACC data
forms [28] by a neuropathologist (RK). Atherosclerosis
and arteriolosclerosis were frequently observed in the
AD cohort and less so in the DS and control cohorts
(Table 2, Fig 1). In contrast, CAA was more common in
the DS cohort (Fig. 1). The relative risks of each of these
vascular outcomes are provided in Table 3 and suggest
that the DS cohort was 1.21 times more likely to have
CAA relative to AD cases, and 4.6 times more likely to
have CAA compared to control cases.
To test the hypothesis that the DS cohort had a higher
frequency of more severe CAA and a lower frequency of
severe atherosclerosis or arteriolosclerosis, we used a cumulative logistic regression analysis. Based on a χ2 test
with 2 degrees of freedom, there was a significant association of CAA with the type of autopsy cohort (Likelihood
ratio statistic 47.96, p < .0001). Cumulative logistic regression may be used to compare the odds of a higher-versuslower severity finding between cohorts based on the odds
ratio. According to Table 4, the odds of severe CAA in the
DS cohort was approximately three times the odds of a
higher severity finding in the AD cohort (odds ratio = 3.05
(95% CI 1.4, 6.67), p = 0.005). Arteriolosclerosis, in
Table 2 NACC cerebrovascular outcomes by cohort showing
the frequency and percentages for each level of severity
Cohort
Characteristic

AD (n = 80)

DS (n = 32)

Ctrl (n = 37)

Not assessed

2 (2.5%)

0 (0%)

0 (0%)

None

34 (42%)

24 (75%)

9 (24%)

Mild

28 (35%)

5 (16%)

16 (43%)

Moderate

11 (14%)

2 (6.2%)

9 (24%)

Severe

4 (5%)

0 (0%)

3 (8.1%)

Missing

1 (1.2%)

1 (3.1%)

0 (0%)

Atherosclerosis

Arteriolosclerosis
Not assessed

0 (0%)

0 (0%)

0 (0%)

None

43 (54%)

31 (97%)

21 (57%)

Mild

21 (26%)

0 (0%)

9 (24%)

Moderate

12 (15%)

0 (0%)

6 (6%)

Severe

3 (3.8%)

0 (0%)

1 (2.7%)

Missing

1 (1.2%)

1 (3.1%)

0 (0%)

Not assessed

0 (0%)

0 (0%)

0 (0%)

None

22 (28%)

4 (12%)

30 (81%)

Mild

32 (40%)

8 (25%)

4 (11%)

Moderate

11 (14%)

7 (22%)

3 (8.1%)

Severe

14 (18%)

12 (38%)

0 (0%)

Missing

1 (1.2%)

1 (3.1%)

0 (0%)

CAA
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contrast, was absent in the DS cohort, and there were no
significant differences between the AD and control
cohorts. Atherosclerosis was significantly less severe in the
DS cases relative to the AD (odds ratio = 0.23, (95% CI
0.09, 0.59), p = 0.0026) and control cases (odds ratio = 0.11,
(95% CI 0.04, 0.30), p < .0001).
Atherosclerosis, arteriolosclerosis and age in DS, AD
and controls

As shown in Fig. 2, the DS cohort is younger than the
AD and control cohorts. The relative youth of the DS
cohort may explain the absence of arteriolosclerosis,
while control (16/37 = 43%) and AD cases (36/80 = 45%)
(Table 2) showed mild to severe arteriolosclerosis (Fig. 3).
Similarly the relative youth may explain the low frequency of atherosclerosis in DS cohort (7/31 = 22.6%
-Table 2) and these lesions were in the mild to moderate
range (Fig. 4), whereas the frequencies in AD and
control cohorts were 43/77 (55.8%) and 28/37 (75.7%),
respectively (Table 2). However, in cases that were under
70 years of age, only one control case showed mild arteriolosclerosis and 6 sporadic AD cases showed mild to
moderate arteriolosclerosis. Atherosclerotic lesions were
observed in a subset of DS cases (25.3%) and these
lesions were in the mild to moderate range (Fig. 4). To
determine whether younger sporadic AD cases and controls show less frequent and severe atherosclerosis comparable to our DS cohort, we separated the bottom 10%
of the AD and control cohorts such that they overlapped
with the overall age distribution of the DS cohort. This
cutoff left 4 control cases and 8 AD cases. The younger
controls showed no CAA, no atherosclerosis and only
one case had mild arteriolosclerosis. In contrast, one AD
case showed mild atherosclerosis, one showed moderate
arteriolosclerosis and almost half showed CAA.
CAA severity increases with age in DS cases

Participants in the DS cohort were on average 20 to
25 years younger at autopsy than participants in the AD
or Control cohorts (Fig. 2). The strong separation between the groups, that is DS versus AD plus Control,
meant that age-at-autopsy and cohort were effectively
confounded in any attempt to account for their relative
contributions to the observed distribution of CAA. We
found it productive, however, to address the question by
analysis of the association with age-at-autopsy in each
cohort, separately. Our results showed in particular that
age-at-autopsy was strongly correlated with CAA severity among DS participants, but not among participants
in the AD or the Control cohorts (Fig. 5). Thus, using a
cumulative logistic regression model with CAA severity
as the dependent variable, we estimated the probability
of the severity of CAA based on age at autopsy for each
cohort. In each case the null model, excluding age as
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Fig. 1 Percentage of autopsy cases by severity of cerebrovascular outcome and cohort. Percentages for Atherosclerosis, Arteriolosclerosis, and
Cerebral Amyloid Angiopathy (CAA) add to 100% within each cohort, separately. More moderate and severe CAA findings were associated
particularly with the DS cohort

predictor, was compared to the alternative model, including age as predictor, using a Chi-squared likelihood
ratio statistic (LRS) based on 1 degree of freedom (df ).
The results showed that a trend with age-at-autopsy was
strongly associated with CAA finding in the DS cohort
at the 5% level of significance (LRS = 6, df = 1, P-value
= 0.014). Again at the 5% level of significance, the
results also showed that age-at-autopsy was not significantly associated with CAA findings in the AD cohort
(LRS = 0.57, df = 1, P-value = 0.45) nor in the Control
cohort (LRS = 2.43, df = 1, P-value = 0.119).
Figure 6 graphs the estimated probability curves for
the DS cohort. The estimated probability of a severe
finding is shown as an increasing function of age and becomes the most likely finding at about age 54 years. A
finding of ‘none’ is shown as the most likely finding before age 43 years, beyond which the most likely finding
was estimated to be ‘mild’, at least until the age of about
54 years. Figure 5 graphs the estimated probabilities of
each finding at selected ages, including a 95% confidence
interval for the population value. At younger ages, say
46 to 50 years in Fig. 5, the confidence intervals overlap
appreciably among the various findings. But at the older
ages, say 56 years and above, the intervals separate, and

the likelihood of a severe finding tends to dominate.
Note that above age 59 years in DS, severe CAA was
more common than mild or moderate CAA. In contrast
to these results, the estimated probability curves (not
shown) were basically flat in the AD and Control cohorts,
reflecting the non-significant trends with age-at-autopsy
in these groups. Nevertheless, the observed trends in the
DS cohort appeared to be of independent interest.

Discussion and conclusions
We hypothesized that people with DS would have
significantly more frequent and more severe CAA
associated with overexpression of APP relative to
sporadic AD and control cases but less cerebrovascular pathology typically associated with cardiovascular
risk factors including atherosclerotic lesions and arteriolosclerosis. In the current study, as expected, we
found: (1) the presence of CAA in DS was more
frequent than in the AD and control cohorts; (2) that
the DS cohort showed an increased probability of
more severe CAA with age; and (3) atherosclerosis
and arteriolosclerosis vascular pathology was uncommon in DS.

Head et al. Acta Neuropathologica Communications (2017) 5:93
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Table 3 Relative risk of cerebrovascular outcome for participants
with pairwise comparisons among the cohorts. Each outcome
was dichotomized to indicate the presence versus absence of the
finding. Relative risk was calculated and reported with the 95%
confidence based on the score test for binomial outcomes
Relative Riska

DS vs AD
Cerebrovascular outcome AD (n = 80)

DS (n = 32)

Estimate (95% CI)

Atherosclerosis

43 (55.84%)

7 (22.58%)

0.40 (0.20, 0.74)

Arteriolosclerosis

36 (45.57%)

0 (0.00%)

0.00 (0.00, 0.24)

CAA

57 (72.15%)

27 (87.10%) 1.21 (0.96, 1.46)

DS vs Ctrl

Atherosclerosis

Relative Risk
Ctrl (n = 37) DS (n = 32)

Estimate (95% CI)

28 (75.68%)

7 (22.58%)

0.30 (0.15, 0.55)
0.00 (0.00, 0.26)

Arteriolosclerosis

16 (43.24%)

0 (0.00%)

CAA

7 (18.92%)

27 (87.10%) 4.60 (2.49, 9.29)

AD vs Ctrl

Relative Risk
Ctrl (n = 37) AD (n = 80) Estimate (95% CI)

Atherosclerosis

28 (75.68%)

43 (55.84%) 0.74 (0.56, 0.99)

Arteriolosclerosis

16 (43.24%)

36 (45.57%) 1.05 (0.70, 1.68)

CAA

7 (18.92%)

57 (72.15%) 3.81 (2.07, 7.70)

a

Cerebrovascular outcomes were dichotomized for the presence vs the absence
of positive finding. Relative risk compares DS to AD, DS to Control and AD to
Control. The confidence intervals were calculated using the score test for the
binomial distribution

CAA in controls, AD and DS

The current study observed CAA in 87.1% of DS cases,
18.9% of controls and 72.2% of AD cases. This is significantly higher than a previous report using neuroimaging
outcomes to detect microbleeds in a larger cohort [14].
Table 4 Pairwise comparisons among cohorts for each of the
vascular outcome measures. The odds ratio (OR) of a higher-level
finding was compared among cohorts. Estimated odds used
cumulative logistic regression to model the chance of higherversus-lower severity outcome based on an indicator of the
cohort. For arteriolosclerosis, only the AD versus Ctrl comparison
could be reliably estimated

Fig. 2 Age at autopsy across the three cohorts (DS, AD, Ctrl) showing
that the DS cases were younger than the AD and Control (Ctrl) cases.
Individual data points are shown in open circles, group means in solid,
red circles. Error bars show plus-and-minus one standard deviation
from the mean

In a separate study, the frequency of CAA in a prospectively followed cohort of nondemented individuals without DS (n = 59 cases with an average age of 83.9 years at
autopsy) has been reported as high as 62% [17]. In contrast, in a NACC study of 140 nondemented control
cases without AD neuropathology with an average age at
death of 83.5 years, 7.5% exhibited CAA [9]. The NACC
study was consistent with the Medical Research Council
of Cognitive Function and Ageing Study in England and
Wales where 7% of 109 nondemented control cases (70–
103 years) exhibit CAA [44]. In contrast, the Adult
Changes in Thought (ACT) study noted that 15.7% of
control cases (n = 89, 70 years to over 90 years) had

Odds Ratios (OR) among Cohorts
Est. (95% CI)

P-value

AD vs Ctrl

0.46 (0.22, 0.95)

0.0353

140

AD vs Ctrl

0.46 (0.22, 0.95)

0.0353

140

DS vs Ctrl

0.11 (0.04, 0.30)

< 0.0001

140

DS vs AD

0.23 (0.09, 0.59)

0.0026

140

1.08 (0.51, 2.32)

0.8376

142

AD vs Ctrl

10.12 (3.94, 25.96)

< 0.0001

142

DS vs Ctrl

30.88 (10.15, 93.99)

< 0.0001

142

DS vs AD

3.05 (1.40, 6.67)

0.0055

142

Vascular finding

df

Atherosclerosis

Arteriolosclerosis
AD vs Ctrl
CAA
Fig. 3 Arteriolosclerosis as a function of age in DS, AD and Controls.
Individual data points shown as open circles, group means as filled
circles. Error bars show plus-and-minus one standard deviation from
the mean

Head et al. Acta Neuropathologica Communications (2017) 5:93
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Fig. 4 Atherosclerosis as a function of age in DS, AD and Controls.
Individual data points shown as open circles, group means as filled
circles. Error bars show plus-and-minus one standard deviation from
the mean

Fig. 6 Probability curves for CAA severity based on age-at-autopsy
in DS cohort. The age at which CAA shifts from mild, to moderate to
severe are estimated based on age. Moderate to severe findings were
more likely at upper ages

CAA [54]. In studies of AD cases, consistently more frequent CAA is observed that range between 37%–83% of
autopsy cases [22, 44, 49, 54]. Thus, the range of cases
affected by CAA in our AD and control cohorts is not
inconsistent with previous reports.
The presence of CAA in 87.1% of DS cases is high both
relative to the AD cohort examined here as well as previous
reports in nondemented controls and AD cases, suggesting
that CAA may be a critical vascular pathology associated
with aging in DS. A recent neuroimaging study using T2*based MR outcome measures observed that CAA was
present in 31% of cognitively impaired people with DS [14].
More frequent CAA is observed in autosomal dominant AD subjects, who also exhibit Aβ overproduction

and develop early onset AD. In a study by Ringman and
colleagues, autosomal dominant AD cases who were of
similar age to the current cohort of DS autopsy cases
(average age 53.5 years) showed more moderate to severe CAA (63.3%) as compared to older sporadic AD
cases (39.2%, mean age 79.3 years) [49]. In contrast, in
rare autopsy cases of DS with partial trisomy 21, where
APP is not overexpressed, AD neuropathology and CAA
was absent even at 72 or 78 years of age at autopsy [19,
46]. Thus, higher levels of CAA in DS are most likely
due to APP overexpression and consequent increased
Aβ accumulation. CAA in people with DS is more consistent with the CAA prevalence in early onset autosomal dominant AD.

Fig. 5 Probability of CAA severity as a function of age-at-autopsy in DS cohort. Error bars show the upper and lower limits of the 95% confidence
interval. The number of DS cases with no or mild CAA decreases with age. The number of people with DS with moderate CAA remains relatively
stable but the numbers of cases with severe CAA increases with age

Head et al. Acta Neuropathologica Communications (2017) 5:93

Arteriolosclerosis and Atherosclerosis in AD, controls
and DS

Atherosclerosis and arteriolosclerosis were uncommon
in the DS cohort, which may be due to their younger
ages (50–59 years). In a NACC study of older nondemented autopsy cases lacking AD pathology, 77.6% of
cases showed arteriolosclerosis and 82.9% showed atherosclerosis (n = 140, mean age 83.5 years) [9]. In studies
of nondemented autopsy cases under 70 years of age
(50–70 years), 68.6% (n = 1008) were positive for arteriolosclerosis [29]. Further, Ighodaro et al. showed using
NACC autopsy data from cases at an average age of
50 years that only 20% exhibited arteriolosclerosis.
Implications of CAA in DS

The contribution of CAA pathology to the development
of AD neuropathology and/or dementia is increasingly
recognized as being critical [33, 55]. Further, cerebrovascular lesions may be one of the underlying causes of
variable (and modest) clinical trial outcomes as they may
be more or less engaged in individual patients and possibly blunting responses to Aβ interventions. In DS, the
higher frequency of CAA is likely to lead to several
possible outcomes: First, CAA can lead to vascular dysfunction including impaired constriction and dilation,
which is consistent with reports of reduced FDG-PET
with age in DS and also associated with cognitive decline
[51]. Second, CAA can lead to blood brain barrier
disruptions and microhemorrhages [50, 58], which also
may contribute (in addition to APP overexpression) to
the earlier age of onset of dementia in people with DS.
Interestingly, a recent review by Buss and colleagues
suggests that despite the presence of CAA in DS, there
appears to be less intracerebral hemorrhage suggesting
possible protective mechanisms; this will be an exciting
avenue of research for future studies [13].
It is important to consider some caveats to the current
study, which include the use of observational data, the
relatively small sample size of our DS cohort and the
younger age of this cohort. Autopsy studies of DS are a
challenge as the number of tissue donations are relatively small, thus our samples size is smaller relative to
sporadic AD cohorts. Further, people with DS who
volunteered for this research study and consented to
autopsy may also represent a biased sample. Age is virtually impossible to control for in the comparison of these
three groups as people with DS have a significantly
younger age of onset of AD neuropathology and development of dementia.
The higher frequency of CAA in DS compared to
sporadic AD is interesting in that cerebrovascular pathology in DS appears to have a unique signature, i.e. significant CAA and low or absent atherosclerosis and
arteriolosclerosis, which could impact cognition and age
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of onset of dementia in DS. Weller et al. have suggested
that CAA may impact therapeutic outcomes and may
predispose people to vasogenic edema and hemorrhagic
complications due to reduced drainage of Aβ associated
with affected vessels [59]. Experimental evidence by the
same group shows that periarterial lymphatic drainage is
impaired with age and CAA. With an increase in production of Aβ in DS it seems likely that CAA and the
presence of Aβ plaques would form at a younger age
and with less severity of arteriolosclerosis in DS than in
sporadic AD. The present study supports the hypothesis
that a life-long increase in production of Aβ in DS predisposes to an earlier onset of age-related impairment of periarterial elimination of Aβ from the brain and thus may
accelerate the onset of the pathological features of AD [4] .
While the hypothesis of reduced periarterial elimination of Aβ from the brain is compelling, in DS it does
not readily account for findings from other groups of
Aβ’s role in cerebrovascular disease and plasma levels of
Aβ. For example, Gomis and colleagues show that
plasma Aβ1–40 levels are associated with cerebrovascular small vessel disease in acute lacunar stroke and suggest that vascular Aβ is primarily Aβ1–40, which alters
endothelial functions [24]. In DS, plasma data show that
the risk of dementia in DS is increased as levels of Aβ1–42
decline but Aβ1–40 levels increase [53]. As reviewed by
Biffi and Greenberg, a high Aβ 40:42 ratio appears to be an
important index of vascular amyloid formation [10]. However, Carmona-Iragui and colleagues did not find differences in CSF Aβ40 that corresponded to microbleeds by
neuroimaging in DS [14]. Therefore, investigation of
plasma markers and CAA presence in DS as related to
clinical dementia may become an important avenue of
investigation.
If we extend these findings in the context of considering possible interventions for people with DS to prevent
AD, it will be important to target CAA pathology specifically. For example, there is a clinical trial of ponezumab
(PF-04360365) that is specifically targeting CAA as a
treatment for AD that may be very relevant for the DS
population [5, 34]. Thus, CAA pathology in DS may be a
significant factor to consider in the design of future
clinical trials.
In future, it will be important to link neuropathological vascular findings with clinical outcomes (e.g.
severity of dementia in DS) and to further explore the
additional downstream pathologies associated with
CAA. For example, the role of microhemorrhages in DS
and their link to the extent of CAA in DS is as yet unknown. Further it will be interesting in future studies to
distinguish CAA that is associated with capillary Aβ and
associated CAA findings such as microinfarcts, superficial siderosis, etc. Neuroimaging may also provide novel
insights for vascular pathology in DS as has been
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reported previously [14]. Using T2* magnetic resonance
imaging, Carmona-Iragui and colleagues observed CAA
in 31% and 38%, respectively in people with DS who
were nondemented compared with those with dementia.
Linking neuroimaging outcomes to subsequent autopsy
studies will be a challenge for studies of DS but should
evolve over time.
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